102 related articles for article (PubMed ID: 3783454)
1. Noninvasive estimation of bound and mobile platinum compounds in the kidney using a radiopharmacokinetic model.
Brechner RR; D'Argenio DZ; Dahalan R; Wolf W
J Pharm Sci; 1986 Sep; 75(9):873-7. PubMed ID: 3783454
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the distribution in the male rat of platinum-labelled cis-dichlorodiammine platinum (II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum (I), and cis-dichloro-bis-cyclopropylamine platinum (II).
Harrison R; McAuliffe CA; Zaki A; Baer J; Sharma H; Smith A; Jackson H; Fox BW
Cancer Chemother Pharmacol; 1983; 10(2):90-5. PubMed ID: 6682017
[No Abstract] [Full Text] [Related]
3. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
4. Biliary excretion of platinum in rats after administration of cisplatin and aqua(1,1-bis(aminomethyl)-cyclohexane)sulfatoplatinum(II) (spiroplatin, TNO-6).
Van der Vijgh WJ; Verbeek PC; Klein I; Pinedo HM
Cancer Lett; 1985 Aug; 28(1):103-9. PubMed ID: 4040805
[TBL] [Abstract][Full Text] [Related]
5. Uptake and metabolism of cisplatin by rat kidney.
Safirstein R; Miller P; Guttenplan JB
Kidney Int; 1984 May; 25(5):753-8. PubMed ID: 6540826
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).
Lautersztain J; Perez-Soler R; Khokhar AR; Newman RA; Lopez-Berestein G
Cancer Chemother Pharmacol; 1986; 18(2):93-7. PubMed ID: 3791565
[TBL] [Abstract][Full Text] [Related]
9. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 May; 34(9):1423-8. PubMed ID: 4039567
[TBL] [Abstract][Full Text] [Related]
10. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and toxicodynamics of cisplatin and its metabolites in rats: relationship between renal handling and nephrotoxicity of cisplatin.
Hanada K; Ninomiya K; Ogata H
J Pharm Pharmacol; 2000 Nov; 52(11):1345-53. PubMed ID: 11186242
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
13. Determination of cisplatin and related platinum complexes in plasma ultrafiltrate and urine by high-performance liquid chromatography with on-line radioactivity detection.
Baldew GS; Volkers KJ; De Goeij JJ; Vermeulen NP
J Chromatogr; 1989 Jun; 491(1):163-74. PubMed ID: 2793971
[TBL] [Abstract][Full Text] [Related]
14. Intracellular metabolites of cisplatin in the rat kidney.
Mistry P; Lee C; McBrien DC
Cancer Chemother Pharmacol; 1989; 24(2):73-9. PubMed ID: 2731314
[TBL] [Abstract][Full Text] [Related]
15. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera.
Owens SE; Thatcher N; Sharma H; Adam N; Harrison R; Smith A; Zaki A; Baer JC; McAuliffe CA; Crowther D
Cancer Chemother Pharmacol; 1985; 14(3):253-7. PubMed ID: 3888431
[TBL] [Abstract][Full Text] [Related]
16. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds.
Vermeulen NP; Baldew GS; Los G; McVie JG; De Goeij JJ
Drug Metab Dispos; 1993; 21(1):30-6. PubMed ID: 8095223
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of therapeutic doses of isotopically labeled platinum antitumor agents in the mouse and rat.
Robins AB; Leach MO
Cancer Treat Rep; 1983 Mar; 67(3):245-52. PubMed ID: 6682013
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney.
Hanigan MH; Gallagher BC; Taylor PT
Am J Obstet Gynecol; 1996 Aug; 175(2):270-3; discussion 273-4. PubMed ID: 8765241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
